Embedded Files
Host-pathogen Interaction and Biofilm
A multidrug resistance (MDR) urinary tract infection (UTI) was defined as an infection caused by a uropathogen resistant to three or more classes of antibiotics and it is one of the most common bacterial infectious diseases in the world. More than 50% of the female population have witnessed one UTI and more than 25% witnessing a second episode of a UTI. The bacterial adhesin FimH is a virulence factor and an attractive therapeutic target for UTI and other infectious diseases. FimH is a bacterial adhesin that helps bacteria such as Escherichia coli (E. coli) to bind to host cells and their receptors. Located on type 1 pili of uropathogenic E. coli (UPEC), the FimH adhesin plays an integral role in the pathogenesis of UPEC. The goal of our study is to design and discover of FimH targeting inhibitor to block the binding of bacteria to host cells.
Drug Resistance and Beta-Lactamases
The major goal of the project is to develop a novel class of potent β-lactamase inhibitors to rescue existing β-lactam antibiotic activities for combination antibacterial therapy. The ability to preserve the efficacy of existing β-lactam antibiotics arsenal provides maximum opportunity for combination antimicrobial therapy development. To achieve this objective, we will use a state-of-the-art drug design methodology involving computational molecular modeling, cell & enzyme-based study, and chemical synthesis to generate inhibitors of a β-lactamase protein.
Drug Resistance Pattern Identification
$1.5 billion is being spent each year on the cost of community and hospital-acquired infections due to antibiotic resistance. Beta-lactam antibiotics are important primary therapeutic agents to combat common bacterial infections; however, the resistance of ESKAPE (Enterococcus, Staphylococcus, Klebsiella, Acinetobacter, Pseudomonas) pathogens to β-lactam antibiotics has created numerous global public health problems. With a limited number of antibiotics approved in recent years, developing combination antibacterial therapy with an established or novel β-lactamase inhibitor remains a viable strategy for overcoming β-lactam drug resistance. Rationally, such endeavor requires the identification and characterization of the drug resistance causing β-lactamase. Therefore, effective therapy in the treatment of resistant bacteria is necessary and, to achieve this, a detailed understanding of mechanisms that underlie drug resistance must be sought.
Abnormal Protein Aggregation in Neurological Disorders
Research in my lab focuses on computational structural biology and drug design for Alzheimer’s disease (AD), and other neurodegenerative disorders. The ultimate goal is to identify unprecedented drug targets, develop effective therapeutic strategies, and design new lead compounds for the treatment of neurodegenerative and other brain diseases. I have a well-balanced research background and laboratory environments in medicinal-chemistry / cell-biology including extensive expertise in computer-aided drug design (CADD) techniques for this proposed application. The primary goal of the proposed studies is to identify novel therapeutic targets for developing new drugs to treat AD. To accomplish this, we will integrate structural, computational, and cellular approaches to elucidate the underlying mechanisms of how the regulation of neuronal cell surface receptors prevents and slows the disease.
SHIN Lab is affiliated with the College of Pharmacy at NEOMED.
Postal Address: 4209 state route 44, Rootstown, Ohio, 44272 USA
Page updated
Google Sites
Report abuse